Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Auditor change
Appointed director
Quarterly results
Director departure
CAPRICOR THERAPEUTICS, INC. (CAPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE"
05/11/2023 8-K Quarterly results
Docs: "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE"
11/10/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Final Data at Late-Breaking Oral Presentation at the 2021 World Muscle Society Virtual Congress- -Met Primary Efficacy Endpoint of Mid Performance of Upper Limb v1.2 - CAP-1002 – Capricor’s Cell Therapy Program for COVID-19 -Phase 2 INSPIRE Trial Enrollment Complete with 63 Patients Randomized- Capricor’s Exosomes Platform Technology -Completing Non-Clinical Studies for IND Submission- -Pipeline Expansion Underway Using Engineered Exosomes- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, CA Nov. 9, 2021 -- Capricor Therapeutics , a biotechnology company focused on the development of transformative cell and exosome-ba..."
08/12/2021 8-K Quarterly results
Docs: "CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance- -Commencing Start-Up Activities for Pivotal Trial- -Phase II, HOPE-2 Final Data Submitted for Publication- CAP-1002 – Capricor’s Cell Therapy Program for COVID-19 -Phase II INSPIRE Trial Enrollment Nearing Completion- Capricor’s Exosomes Platform Technology -Positioning Multivalent Exosome-mRNA Vaccine as Booster to Currently Available Vaccines- -Completing Non-Clinical Studies for IND Submission- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, CA Aug. 12, 2021 -- Capricor Therapeutics , a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of..."
05/13/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "CAPRICOR THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 REVENUE Revenue $ 16,863 $ 142,071 $ 252,420 $ 782,928 TOTAL REVENUE 16,863 142,071 252,420 782,928 OPERATING EXPENSES Research and development 2,629,267 857,764 5,711,896 4,313,056 General and administrative 1,301,673 911,968 4,049,955 2,720,391 TOTAL OPERATING EXPENSES 3,930,940 1,769,732 9,761,851 7,033,447 LOSS FROM OPERATIONS OTHER INCOME Investment income 3,953 21,061 30,335 80,840 Loss on disposal of fixed asset"
11/09/2020 8-K Quarterly results
Docs: "Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19 Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy"
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/18/2020 8-K Quarterly results
Docs: "CAPRICOR THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three months ended December 31, Years ended December 31, 2019 2018 2019 2018 REVENUE Revenue $ 222,100 $ 648,082 $ 1,005,028 $ 1,671,356 TOTAL REVENUE 222,100 648,082 1,005,028 1,671,356 OPERATING EXPENSES Research and development 828,749 2,849,377 5,141,805 12,066,800 General and administrative 876,720 1,104,670 3,597,111 4,931,642 TOTAL OPERATING EXPENSES 1,705,469 3,954,047 8,738,916 16,998,442 LOSS FROM OPERATIONS OTHER INCOME Investment income 13,951 46,086 94,791 135,991 Loss on disposal of fixed asset - - - TOTAL OTHER INCOME 13,951 46,086 92,071 135,991 NET LOSS OTHER COMPREHENSIVE INCOME Net unrealized gain on marketable securities 773 COMPREHENSIVE LOSS $ $ $ $ Net loss per share, basic ..."
11/07/2019 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update"
08/06/2019 8-K Quarterly results
05/13/2019 8-K Quarterly results
Docs: "Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET , May 13, 2019 – Capricor Therapeutics , a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the first quarter 2019 and provided a corporate update. “We continue with the clinical development of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. Our HOPE-2 clinical trial, which is testing t..."
03/28/2019 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET , March 28, 2019 – Capricor Therapeutics , a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the fourth quarter and full year 2018 and provided a corporate update. “This has been a busy year for Capricor as we continue with the clinical development of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and ..."
11/13/2018 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today at 4:30 p.m. ET , November 13, 2018 – Capricor Therapeutics , a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the third quarter of 2018, which ended September 30, 2018, and provided a corporate update. “Capricor continues its progress in the clinical development of our novel cell therapy, CAP-1002, to treat Duchenne muscular dystrophy, and we are moving forward with our exosome-based therapy, CAP-2003,” said Linda Marbán, Ph.D., Capricor CEO. “Our HOPE-2 clinical trial, wh..."
08/09/2018 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today at 4:30 p.m. ET , August 9, 2018 – Capricor Therapeutics , a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the second quarter, which ended June 30, 2018, and provided a corporate update. “Capricor continues to move forward with the clinical development of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. “We are actively enrolling patients in HOPE-2, with multiple sites..."
05/10/2018 8-K Quarterly results
Docs: "Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 – Capricor Therapeutics , a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the first quarter, which ended March 31, 2018, and provided a corporate update. “We are excited by the recent initiation of the HOPE-2 clinical trial of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. “CAP-100..."
11/08/2017 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program"
08/10/2017 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update",
"Capricor Therapeutics, Inc. Corporate Update Presentation"
05/15/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/15/2016 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update"
05/12/2016 8-K Quarterly results
Docs: "Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results"
03/17/2016 8-K Form 8-K - Current report
11/12/2015 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights"
08/13/2015 8-K Quarterly results
Docs: "Second Quarter and Recent Operational Highlights · Received FDA clearance for the HOPE-DUCHENNE Phase I/II trial of cardiosphere derived cell therapy, CAP-1002, for the treatment of Duchenne muscular dystrophy -related cardiomyopathy · Received orphan drug designation from the FDA for CAP-1002 for the treatment of DMD-related cardiomyopathy · Completed enrollment of the DYNAMIC clinical trial of CAP-1002 for the treatment of advanced heart failure · Appointed Deborah Ascheim, M.D., a heart failure cardiologist with significant experience directing national and international clinical trials, as Chief Medical Officer · Appointed Houman Hemmati, M.D., Ph.D., as Vice President of Medical and Clinical Development for New Therapies, who will be responsible for ..."
05/12/2015 8-K Quarterly results
Docs: "First Quarter and Recent Operational Highlights · Raised approximately $17.0 million in two private placements of common stock · Initiated the DYNAMIC trial to evaluate CAP-1002 in patients with advanced heart failure; the trial is funded in part through an approximate $3.0 million grant from the National Institutes of Health · Appointed Thomas Copmann, Ph.D., as Vice President of Regulatory Affairs and Drug Development · Commenced trading of Capricor common stock on the Nasdaq Capital Market effective March 9, 2015 · Initiated patient enrollment of a dose-ranging Phase II clinical trial of Cenderitide to evaluate the safety and feasibility of delivering the product via a subcutaneous drug delivery patch pump in 14 patients with stable, chronic heart fail..."
11/12/2014 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights"
08/13/2014 8-K Quarterly results
Docs: "Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights"
08/18/2009 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy